Cellectis Prices American Depositary Shares, Expects to Go Public Today | GenomeWeb

NEW YORK (GenomeWeb) – Gene editing firm Cellectis today priced its initial public offering of 5.5 million American Depositary Shares at $41.50 per ADS.  

Each ADS represents one share of the Paris-based firm. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.